UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2010
Neurologix, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-13347 | 06-1582875 | ||
| (State or other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| One Bridge Plaza, Fort Lee, New Jersey |
07024 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (201) 592-6451
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On June 22, 2010, Neurologix, Inc. issued a press release announcing the results of its Phase 2 clinical trial for its
Parkinson’s disease gene transfer therapy. A copy of the press release is being filed as Exhibit 99.1 and is
incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release of Neurologix, Inc., dated June 22, 2010.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Neurologix, Inc. | |||
By:
|
/s/ Marc L. Panoff | ||
Name:
|
Marc L. Panoff | ||
Title:
|
Chief Financial Officer, Secretary and Treasurer | ||
Date: June 22, 2010
EXHIBIT INDEX
| Exhibit No. | Description | |
99.1
|
Press release of Neurologix, Inc., dated June 22, 2010. |